<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149776">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01980888</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-312-0123</org_study_id>
    <secondary_id>2013-003313-17</secondary_id>
    <nct_id>NCT01980888</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Croatia: Agency for Medicinal Product and Medical Devices</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Portugal: INFARMED, National Authority of Medicines and Health Products, IP</authority>
    <authority>Romania: National Agency for Medicines and Medical Devices</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of the addition of idelalisib to bendamustine and
      rituximab on minimal residual disease (MRD) and evaluate the progression-free survival (PFS)
      in participants with previously untreated chronic lymphocytic leukemia (CLL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Minimal residual disease negativity rate</measure>
    <time_frame>Week 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Minimal residual disease (MRD) negativity rate is defined as the proportion of subjects with MRD &lt; 10^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation or at least 12 weeks after the last dose of rituximab for participants receiving the final dose of rituximab after the original scheduled date.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Baseline to Year 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Baseline to Year 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall response rate (ORR) is defined as the proportion of participants who achieve a complete or partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nodal response rate</measure>
    <time_frame>Baseline to Year 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Nodal response rate is defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Baseline to Year 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete response rate is defined as the proportion of participants who achieve a complete response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Baseline to Year 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival is defined as the interval from randomization to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Idelalisib+bendamustine+rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive idelalisib for 96 weeks, bendamustine for 6 months, and rituximab for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idelalisib placebo+bendamustine+rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive placebo to match idelalisib for 96 weeks, bendamustine for 6 months, and rituximab for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <description>Idelalisib 100 mg or 150 mg tablets administered orally twice daily</description>
    <arm_group_label>Idelalisib+bendamustine+rituximab</arm_group_label>
    <other_name>GS-1101</other_name>
    <other_name>CAL-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine 25 mg or 100 mg administered intravenously at a starting dose of 90 mg/m2</description>
    <arm_group_label>Idelalisib+bendamustine+rituximab</arm_group_label>
    <arm_group_label>Idelalisib placebo+bendamustine+rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 100 mg or 500 mg single-use vials administered intravenously weekly starting at 375 mg/m2 on Day 1 (Week 0) and 500 mg/m2 thereafter</description>
    <arm_group_label>Idelalisib+bendamustine+rituximab</arm_group_label>
    <arm_group_label>Idelalisib placebo+bendamustine+rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib placebo</intervention_name>
    <description>Placebo to match idelalisib administered orally twice daily</description>
    <arm_group_label>Idelalisib placebo+bendamustine+rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Documented diagnosis of B-cell CLL, with diagnosis established according to
             International Workshop on Chronic Lymphocytic Leukemia (IWCLL)

          -  No prior therapy for CLL other than corticosteroids for disease complications

          -  CLL that warrants treatment

          -  Presence of measurable lymphadenopathy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

        Exclusion Criteria

          -  Known histological transformation from CLL to an aggressive lymphoma (ie, Richter
             transformation)

          -  Known presence of myelodysplastic syndrome

          -  Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
             randomization

          -  Ongoing liver injury

          -  Ongoing drug-induced pneumonitis

          -  Ongoing inflammatory bowel disease

          -  History of prior allogeneic bone marrow progenitor cell or solid organ
             transplantation

          -  Ongoing immunosuppressive therapy other than corticosteroids

          -  Concurrent participation in another therapeutic clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Adewoye, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Wong</last_name>
    <email>michelle.wong@gilead.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Guillet</last_name>
    <email>susan.guillet@gilead.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beaver Medical Group, L.P.</name>
      <address>
        <city>Highland</city>
        <state>California</state>
        <zip>92346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emad Ibrahim, MD</last_name>
      <phone>909-425-3372</phone>
      <email>Eibrahim@epiclp.com</email>
    </contact>
    <investigator>
      <last_name>Emad Ibrahim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richy Agajanian</last_name>
      <phone>562-693-4477</phone>
      <email>ragajanian@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Richy Agajanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Central Connecticut</name>
      <address>
        <city>Southington</city>
        <state>Connecticut</state>
        <zip>06489</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark J Turney</last_name>
      <phone>860-621-9316</phone>
      <email>mjt2716@sbcglobal.net</email>
    </contact>
    <investigator>
      <last_name>Peter Byeff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehdi Moezi</last_name>
      <phone>904-264-6201</phone>
      <email>mehdi.moezi@CSNF.US</email>
    </contact>
    <investigator>
      <last_name>Mehdi Moezi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montgomery Cancer Center</name>
      <address>
        <city>Mount Sterling</city>
        <state>Kentucky</state>
        <zip>40353</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Zaydan</last_name>
      <phone>859-499-1000</phone>
      <email>mzayden@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Muhammad Zaydan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Boccia</last_name>
      <phone>301-571-0019</phone>
      <email>rboccia@ccbdmd.com</email>
    </contact>
    <investigator>
      <last_name>Ralph Boccia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology /Oncology Associates of Northern New Jersey</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Farber</last_name>
      <phone>973-538-5210</phone>
      <email>mmackenzie@hoannj.com</email>
    </contact>
    <investigator>
      <last_name>Charles Farber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nashat Gabrail</last_name>
      <phone>330-492-3345</phone>
      <email>research@gabrailcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Signal Point Clinical Research Center</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nandagopal Vrindavanam</last_name>
      <phone>513-217-4809</phone>
      <email>nvrindavanam@cinci.rr.com</email>
    </contact>
    <investigator>
      <last_name>Nandagopal Vrindavanam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howland Crosswell, MD</last_name>
      <phone>864-546-3699</phone>
      <email>Howland_Croswell@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Howland Crosswell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Lakes Healthcare System Inc.</name>
      <address>
        <city>Watertown</city>
        <state>South Dakota</state>
        <zip>57201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amin Bipinkumar</last_name>
      <phone>605-882-6800</phone>
      <email>bipin.amin@prairielakes.com</email>
    </contact>
    <investigator>
      <last_name>Amin Bipinkumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>November 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bendamustine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
